Equillium (NASDAQ:EQ) Coverage Initiated at Roth Mkm

Analysts at Roth Mkm started coverage on shares of Equillium (NASDAQ:EQ) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Roth Mkm’s target price indicates a potential upside of 385.83% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Equillium from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Equillium in a report on Monday, December 29th. Stifel Nicolaus started coverage on shares of Equillium in a research note on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target on the stock. Finally, Zacks Research raised shares of Equillium to a “hold” rating in a report on Thursday, February 26th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Equillium has a consensus rating of “Hold” and a consensus target price of $6.00.

Equillium Price Performance

Equillium stock opened at $2.47 on Friday. The business has a 50 day simple moving average of $1.54 and a 200-day simple moving average of $1.42. Equillium has a 12 month low of $0.27 and a 12 month high of $2.63. The stock has a market capitalization of $150.40 million, a PE ratio of -3.98 and a beta of 1.81.

Insider Transactions at Equillium

In other Equillium news, COO Christine Zedelmayer sold 185,937 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $1.76, for a total value of $327,249.12. Following the completion of the sale, the chief operating officer owned 191,444 shares of the company’s stock, valued at approximately $336,941.44. This trade represents a 49.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 485,589 shares of company stock valued at $863,704 in the last three months. Corporate insiders own 31.60% of the company’s stock.

Hedge Funds Weigh In On Equillium

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Aberdeen Group plc purchased a new position in shares of Equillium in the 3rd quarter valued at about $543,000. Persistent Asset Partners Ltd purchased a new stake in Equillium during the third quarter worth about $99,000. Two Sigma Investments LP acquired a new position in Equillium during the third quarter worth about $190,000. Schonfeld Strategic Advisors LLC acquired a new position in Equillium during the third quarter worth about $178,000. Finally, Boothbay Fund Management LLC purchased a new position in Equillium in the third quarter valued at about $174,000. 27.05% of the stock is owned by institutional investors and hedge funds.

Equillium News Summary

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: RA Capital committed roughly $35 million through a definitive PIPE to advance EQ504 and fund operations into 2029, materially strengthening Equillium’s balance sheet and reducing near-term financing risk. Equillium Announces $35 Million Financing with RA Capital Management
• Positive Sentiment: Roth Capital initiated coverage with a Buy rating and a $12 price target, implying large upside vs. the current trading level — this likely amplified bullish sentiment and buying interest. Roth Capital initiates coverage of Equillium (EQ) with buy recommendation
• Neutral Sentiment: A secondary coverage note: Wall Street Zen moved its rating to Hold, a more muted change that is unlikely to move the stock meaningfully versus the PIPE and Roth initiation. Equillium (NASDAQ:EQ) Rating Increased to Hold at Wall Street Zen
• Neutral Sentiment: Company disclosed the transaction structure: ~18.9M common shares (including pre-funded warrants) priced at $1.854 each; proceeds are earmarked for advancing EQ504 and general corporate purposes. Equillium Raises Capital Through Private Equity Securities Sale
• Negative Sentiment: The financing dilutes existing shareholders (issuance of ~18.9M shares) and RA Capital received registration rights — dilution and potential future share sales could weigh on the stock over time. Equillium Secures $35 Million Funding Commitment from RA Capital to Advance EQ504 Clinical Development
• Negative Sentiment: Recent insider selling has been reported, which may concern some investors about near-term insider confidence. QuiverQuant coverage including insider activity

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.